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The mammalian liver is a multifunctional organ with a unique ability to regenerate 46 following tissue injury. This evolutionary adaptation sets the liver apart from other 47 organs, enabling it to detoxify various drugs and toxins whilst simultaneously 48 regenerating after injury. Despite this well-orchestrated process of regeneration, 49 mortality rates from liver disease have continued to rise inexorably since the 1970s 1 . 50
In advanced chronic liver disease, the regenerative and reparative capacity of the 51 liver diminishes and transplantation is the only curative option for patients . However, there are distinct differences in the immune cell composition and 87 marker expression between humans and rodents, and therefore, as always, care 88 must be taken in extrapolating data from rodents to humans. Despite these 89
limitations, these models continue to give important mechanistic insights into how the 90 immune cell compartment regulates liver regeneration. 91
Partial Hepatectomy (PHx) 93 94
In a clinical setting, liver resection is one of the main treatments for hepatic 95 malignancies and the repair of trauma 9 . To study the mechanisms underpinning this 96 remarkable regenerative process, rodent partial hepatectomy (PHx) has become a 97 standard pre-clinical model, where 2/3 of the rodent liver is removed surgically 7, 9 . 98
Once the lobules are removed, regeneration is initiated immediately, with the 99 remnant lobes enlarging via compensatory hyperplasia, until the original mass of the 100 liver is reached, a process which takes approximately 7 days 7, 10 . These rodent 101 models have facilitated a detailed interrogation of this regenerative process, 102 highlighting cellular kinetics, molecular mechanisms and key signaling pathways 103 10, 11 . Hepatocyte proliferation in C57BL/6 mice peaks around 36-48 hours post-104 resection 12 . This process is mediated by complex cross-talk between hepatocytes 105 and NPCs
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. Importantly, this model does not reflect the significant inflammatory 106 M A N U S C R I P T
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responses that can occur in pathological conditions of human acute and chronic liver 107 injury, where liver regeneration may be compromised. 108
109
AILI 110 111
Acute liver failure (ALF) in humans is associated with high mortality rates, brought 112 about by hepatic parenchymal cell death, extensive intra-hepatic inflammation and a 113 systemic inflammatory response (SIRS) 13, 14 . This overwhelming inflammation 114 contributes to multiple organ dysfunction and death 15 . Acetaminophen (APAP) 115 poisoning is the commonest cause of ALF in western countries 3 . Following ingestion 116 of recommended doses of APAP, hepatocytes are protected against its toxic 117 metabolite: N-acetyl-p-benzoquinone (NAPQI), due to detoxification by glutathione. 118
However, at higher doses of APAP, glutathione is depleted by NAPQI, and leads to 119 hepatocyte death. In toxic injuries, liver regeneration is a dose dependent process, it 120 increases with the extent of hepatic injury until a threshold is reached where 121 increasing hepatic injury inhibits the regenerative process, accelerating the 122 progression to ALF 16 . AILI can be modeled in rodents by a single dose of APAP, 123 with similar histological and biochemical features to those seen in human ALF 15, 17 . 124 125 APAP-induced liver injury (AILI) is a bi-phasic process, initial stages involve 126 hepatocyte necrosis from covalent binding of NAPQI to cellular proteins causing 127 mitochondrial dysfunction, oxidative stress and peroxynitrite formation which then activate NPCs through surface-expressed toll-like receptors (TLRs) 19, 20 .
133
The use of animal models has enabled comprehensive analysis of the primary 134 stages of AILI, which has increased our knowledge of the metabolism of APAP by 135 hepatocytes, and the molecular mechanism by which necrosis occurs 18, 21 . Despite 136 this, the current initial therapeutic options for APAP-induced liver injury (AILI) are 137 limited to the antidote: N-acetyl-cysteine (NAC). NAC reverses hepatotoxicity by 138 quenching NAPQI, targeting the initial stages of the disease, so therefore must be 139 given early after APAP poisoning to be effective 22 . Recent studies have 140 demonstrated that the secondary immune response following hepatocyte death is a 141 crucial determinant in disease progression and contributes to the evolution of extra-142 hepatic features like SIRS and multi-organ dysfunction 13, 15, 23 . 143
144
Immune Regulation of Liver Regeneration 145 146
As the immune system plays a major regulatory role in the hepatic regenerative and 147 reparative response, in this review we will describe the known functional roles of 148 various cell lineages within the immune cell compartment, with emphasis on how 149 these cells determine the outcome of hepatic injury and repair. . The 175 presumed mechanism is that macrophages release pro-reparative cytokines such as 176 interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and hepatocyte growth factor 177 (HGF), to drive hepatocyte proliferation 34 . However, a detailed characterization of 178 macrophage phenotype following PHx remains lacking. Furthermore, elevated 179 colony stimulating factor 1 (CSF1), a mitogen and survival factor for macrophages isM A N U S C R I P T A C C E P T E D . Conversely, Ly6C
Hi monocytes have an 220 overall pro-inflammatory transcription profile, which can aggravate the early phase of 221 AILI 39 . These apparently contradictory findings can be explained by the plasticity of 222
MoMFs. Upon maturation, these pro-inflammatory Ly6C
Hi monocytes acquire a pro-223 reparative phenotype, where angiogenic and tissue remodeling factors such as 224 vascular growth factor A (VEGFA) and fibronectin are upregulated in these cells 38 . 225
They polarize to ephemeral Ly6C
Lo CCR2 Lo CX3CR1 Hi macrophages (MoMFs) that 226 promote angiogenesis, tissue remodeling and necrotic cell clearance 38 ( Figure 2B ). 227
228
These data suggest that specific subsets of macrophages promote a niche which 229 supports clearance of cellular debris and an anti-inflammatory phenotype, promotingM A N U S C R I P T
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live repair and regeneration 40, 53 . In addition to these pro-reparative responses 231 macrophages also have a pivotal role in mediating the broader immune response 232 during AILI. Due to increased gut permeability, the capacity of the liver to maintain 233 an effective immune barrier against gut-derived pathogens is markedly reduced 234 during liver injury 54 . Thus, activation of hepatic macrophages is a key regulatory 235 process during liver injury, not only mediating tissue repair but also combating the 236 influx of pathogens into the liver and preventing their spread systemically 55 . In line 237 with this, sepsis and/or SIRS have been identified as major factors contributing to 238 worsening hepatic encephalopathy in ALF, conferring poor prognosis 13, 15 . 239
240
Macrophages have been shown to be important in human AILI. Pro-inflammatory 241 and pro-resolution monocyte/macrophages, analogous to subsets identified in 242 mouse models of AILI, have also been described in humans 40, 56 . Recent studies in . Blocking these interactions resulted in a significant reduction in 348 systemic inflammation, liver neutrophil recruitment and hepatotoxicity 41, 84 . 349
Conversely, inhibiting neutrophil interaction with target cells, or preventing 350
neutrophil-derived oxidant stress show no effect on hepatotoxicity . 487
There is also an increase in T REG cells in the liver post-AILI, and they display a 
